CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,383,812
- in 18 filings, $13.4M under 10b5-1 plans
Net −$32,383,812. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-18 | ROBINS CHAD M CEO and Chairman | Sale | −204 | $25.14 | $5K | 2,180,518 |
| 2026-08-18 | ROBINS CHAD M CEO and Chairman | Option exercise · Stock Option (right to buy) | −278,676 | 0 | ||
| 2026-08-17 | ROBINS CHAD M CEO and Chairman | Option exercise | +321,324 | $6.55 | $2.1M | 2,501,842 |
| 2026-08-17 | ROBINS CHAD M CEO and Chairman | Sale | −318,799 | $25.08 | $8.0M | 2,183,043 |
| 2026-08-17 | ROBINS CHAD M CEO and Chairman | Sale | −2,525 | $25.57 | $65K | 2,180,518 |
| 2026-08-17 | ROBINS CHAD M CEO and Chairman | Option exercise · Stock Option (right to buy) | −321,324 | 278,676 | ||
| 2026-08-17 | NEUPERT PETER M Director | Option exercise | +15,000 | $6.32 | $95K | 255,315 |
| 2026-08-17 | NEUPERT PETER M Director | Sale | −15,000 | $25.23 | $378K | 240,315 |
| 2026-08-17 | NEUPERT PETER M Director | Sale | −40,000 | $25.10 | $1.0M | 200,315 |
| 2026-08-17 | NEUPERT PETER M Director | Sale | −69,690 | $25.16 | $1.8M | 130,625 |
| 2026-08-17 | NEUPERT PETER M Director | Option exercise · Stock Option (right to buy) | −15,000 | 0 | ||
| 2026-08-10 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale 10b5-1 | −3,000 | $25.00 | $75K | 396,989 |
| 2026-07-30 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale 10b5-1 | −1,299 | $24.00 | $31K | 399,989 |
| 2026-07-21 | ROBINS HARLAN S Chief Scientific Officer | Option exercise 10b5-1 | +284,800 | $6.55 | $1.9M | 1,304,458 |
| 2026-07-21 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −278,698 | $21.72 | $6.1M | 1,025,760 |
| 2026-07-21 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −213,702 | $22.12 | $4.7M | 812,058 |
| 2026-07-21 | ROBINS HARLAN S Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −284,800 | 0 | ||
| 2026-07-16 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale 10b5-1 | −5,000 | $23.00 | $115K | 401,288 |
| 2026-07-15 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 | +59,374 | $7.80 | $463K | 290,087 |
| 2026-07-15 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 | +23,677 | $12.14 | $287K | 313,764 |
Page 8 of 119 · 2,375 trades